NXGL vs LIQT vs XTLB

For growth investors, NEXGEL, Inc.

(NXGL) is the stronger pick with 112. 5% revenue growth year-over-year, versus 13. 0% for LiqTech International, Inc. (LIQT). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, XTL Biopharmaceuticals Ltd.

(XTLB) delivered a total return of -81. 5%, compared to -96. 1% for LiqTech International, Inc. (LIQT). Over 10 years, the gap is even starker: NXGL returned -83. 1% versus LIQT's -91. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), LiqTech International, Inc.

(LIQT) is the lower-risk stock at 0. 54β versus XTL Biopharmaceuticals Ltd. 's 1. 64β — meaning XTLB is approximately 204% more volatile than LIQT relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 117% for LiqTech International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NEXGEL, Inc.

(NXGL) is pulling ahead at 112. 5% versus 13. 0% for LiqTech International, Inc. (LIQT). On earnings-per-share growth, the picture is similar: LiqTech International, Inc. grew EPS 45. 7% year-over-year, compared to 10. 7% for NEXGEL, Inc.. Over a 3-year CAGR, NXGL leads at 77. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

NEXGEL, Inc.

(NXGL) is the more profitable company, earning -37. 8% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps -37. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NXGL leads at -40. 9% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — NXGL leads at 31. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, LiqTech International, Inc.

(LIQT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54)). XTL Biopharmaceuticals Ltd. (XTLB) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LIQT: -91. 0%, XTLB: -87. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NXGL (Healthcare) and LIQT (Industrials) and XTLB (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NXGL is a small-cap high-growth stock; LIQT is a small-cap quality compounder stock; XTLB is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.